BerGenBio ASA (BRRGF) Price & Analysis

Compare

57 Followers

BRRGF Stock Chart & Stats

$0.02

$0.00(0.00%)

At close: Nov 29 4:00 PM EST

$0.02

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.03 - $0.03

Previous CloseN/A

Volume50.00

Average Volume (3M)0.00

Market Cap

$21.86M

Enterprise Value-$11.35M

Total Cash (Recent Filing)$140.16M

Total Debt (Recent Filing)$818.00K

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding447,841,130

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.52

Enterprise Value/Revenue-13.39

Enterprise Value/Gross Profit0.69

Enterprise Value/Ebitda0.08

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBerGenBio launches dual-inhibitor trial with first patient enrolled, focusing on patients with lung adenocarcinoma.

Market OpportunitiesBerGenBio has an opportunity to capture market share by targeting the STK11 mutation in cancer, particularly relevant for lung cancer patients with significant unmet medical need.

Bears Say

Partnership ChallengesIn 2022, BerGenBio announced it would not continue the internal development of tilvestamab due to an inability to secure an attractive partnership on favorable terms.

Product Development IssuesADC Therapeutics informed BerGenBio that the therapeutic window for ADCT-601 is too narrow, likely due to toxicities, impacting its development.

BerGenBio ASA News

Oncoinvent Revamps Option Scheme and Issues New Grants After BerGenBio Merger

BerGenBio ASA ( ($BRRGF) ) has issued an announcement. Oncoinvent ASA, a clinical-stage radiopharmaceutical company listed on the...

11d ago

Oncoinvent Calls Extraordinary General Meeting to Reshape Capital Structure

BerGenBio ASA ( ($BRRGF) ) has shared an update. Oncoinvent ASA, a clinical-stage biotech focused on radiopharmaceutical cancer...

15d ago

Oncoinvent ASA Completes Rights Issue and Share Capital Adjustment

BerGenBio ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA has completed a fully underwritten rights issue,...

23d ago

Oncoinvent’s Radspherin® Shows Promise in Ovarian Cancer Treatment

An update from BerGenBio ASA ( ($BRRGF) ) is now available. Oncoinvent has published promising 12-month data from...

26d ago

Oncoinvent ASA Announces Rights Issue and Underwriting Commission

BerGenBio ASA ( ($BRRGF) ) just unveiled an announcement. Oncoinvent ASA has announced a fully underwritten rights issue,...

26d ago

Oncoinvent ASA Completes Major Rights Issue

BerGenBio ASA ( ($BRRGF) ) just unveiled an update. Oncoinvent ASA has completed a fully underwritten rights issue,...

1M ago

Oncoinvent ASA Completes NOK 130 Million Rights Issue to Bolster Cancer Therapy Development

BerGenBio ASA ( ($BRRGF) ) has issued an update. Oncoinvent ASA has successfully completed a fully underwritten rights...

1M ago

Oncoinvent ASA Completes Subscription Period for Rights Issue

An announcement from BerGenBio ASA ( ($BRRGF) ) is now available. Oncoinvent ASA has concluded the subscription period...

1M ago

Oncoinvent ASA Rights Issue Subscription Period Closes

BerGenBio ASA ( ($BRRGF) ) has issued an announcement. Oncoinvent ASA announced the expiration of the subscription period...

1M ago

Oncoinvent ASA Completes Major Rights Issue with Insider Participation

BerGenBio ASA ( ($BRRGF) ) just unveiled an announcement. Oncoinvent ASA has announced the completion of a significant...

1M ago

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on BerGenBio to NOK 38 from NOK 70...

1y ago

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK...

3y ago

BerGenBio downgraded to Sell from Hold at DNB Markets

DNB Markets downgraded BerGenBio to Sell from Hold with a NOK 1 price target. Published first on TheFly...

3y ago

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now...

3y ago

BRRGF

BRRGF FAQ

What was BerGenBio ASA’s price range in the past 12 months?

BerGenBio ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.

What is BerGenBio ASA’s market cap?

BerGenBio ASA’s market cap is $21.86M.

When is BerGenBio ASA’s upcoming earnings report date?

BerGenBio ASA’s upcoming earnings report date is Feb 19, 2026 which is in 47 days.

How were BerGenBio ASA’s earnings last quarter?

Currently, no data Available

Is BerGenBio ASA overvalued?

According to Wall Street analysts BerGenBio ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BerGenBio ASA pay dividends?

BerGenBio ASA does not currently pay dividends.

What is BerGenBio ASA’s EPS estimate?

BerGenBio ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BerGenBio ASA have?

BerGenBio ASA has 447,841,130 shares outstanding.

What happened to BerGenBio ASA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of BerGenBio ASA?

Currently, no hedge funds are holding shares in BRRGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.